Clomiphene
Clomid · Clomifene
Clomiphene citrate (Clomid, clomifene) is an orally active selective estrogen receptor modulator (SERM) and a racemic mix of two isomers (enclomiphene and the longer-lived zuclomiphene). In men it is used off-label to raise endogenous testosterone by blocking estrogen negative feedback at the hypothalamus/pituitary, which increases LH, FSH and testicular testosterone output while preserving sperm production. Because it stimulates rather than suppresses the HPTA, it is often taken by men wanting to raise testosterone without the fertility loss of exogenous testosterone, or after anabolic steroid use. It is not benign: it raises estradiol (breast tenderness/gynecomastia), and reversible mood changes and visual disturbances (blurred vision, shimmering/scotomata) are reported. As a SERM it carries a class-level theoretical venous thromboembolism risk, and there are no long-term cardiovascular outcome trials in men. Most human data come from small, short-to-medium-term trials in hypogonadal or infertile men; it does not fix an underlying testicular failure, and use should be supervised with bloodwork and an endocrinologist/urologist, not self-directed. This is not medical advice.
Mechanism of action
Pharmacokinetics
Isomer-dependent and non-uniform. Enclomiphene isomer is comparatively short-lived (cleared over a few days); the zuclomiphene isomer has a very long, 'flat' terminal half-life with a long residence time due to its lipophilicity and extensive tissue distribution, and can remain detectable for weeks after a single dose. A discrete single half-life cannot be reliably assigned for the racemate (Ghobadi 2008).
Once-daily or every-other-day oral dosing is used clinically because of accumulation of the long-lived zuclomiphene isomer; biological effect on gonadotropins persists across the dosing interval. Zuclomiphene accumulation means washout after stopping is prolonged (weeks), relevant for monitoring, not for evading testing.
Oral (tablet/capsule).
Hepatic metabolism with enterohepatic recirculation and predominantly fecal excretion; lipophilic distribution into tissues prolongs residence. Human single-dose isomer pharmacokinetics were characterized in women with PCOS; dedicated male pharmacokinetic data are limited (Ghobadi 2008).
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Raises serum total and free testosterone in men with secondary/functional hypogonadism, with meta-analytic total-testosterone increases comparable to those seen with topical testosterone gel
- Increases LH and FSH (stimulates rather than suppresses the HPTA)
- Preserves or increases sperm production, unlike exogenous testosterone which suppresses spermatogenesis
- Raises estradiol (E2) because increased testosterone is partly aromatized
- Improves hypogonadal symptom scores (e.g. ADAM questionnaire) in some trials; effect on erectile function and overall sexual function is inconsistent and in one RCT sexual-function/qADAM scores were not improved versus placebo
- May improve bone mineral density over long-term use in hypogonadal men in one observational cohort
- Associated with modest metabolic changes (reduced HOMA-IR/insulin) in obese dysmetabolic men on concurrent metformin in one RCT
Adverse effects by system
No dedicated cardiovascular outcome trials in men. No excess cardiovascular events were reported in the small/short-to-medium-term trials and meta-analyses, but these were underpowered for cardiovascular endpoints. As a SERM, clomiphene carries a class-level theoretical/labeled risk of venous thromboembolism; clomiphene also raises estradiol, which is mechanistically relevant to thrombotic risk. Long-term cardiovascular safety in men is essentially unknown.
No hepatotoxicity signal reported in the male hypogonadism/infertility trials; clomiphene is not 17-alpha-alkylated. Systematic transaminase reporting is sparse, so a reassuring but low-certainty picture. No adequate long-term hepatic outcome data.
Clomiphene stimulates the HPTA (raises LH, FSH, testosterone and estradiol); it does not suppress it. The main endocrine adverse consequences are estrogen-excess effects from the rise in estradiol (breast tenderness, gynecomastia). It also alters the broader steroid profile (increased DHT, estrone). It will not raise testosterone in primary (hypergonadotropic) hypogonadism.
Distinctively fertility-sparing/stimulating: preserves or increases sperm counts and raises intratesticular androgen output. Estrogen-mediated breast tenderness and gynecomastia can occur from elevated estradiol. Sexual-function effects are inconsistent (some reports of reduced erectile/intercourse-satisfaction scores versus placebo in one RCT despite increased desire).
Reversible mood changes are reported. In a long-term retrospective cohort of 400 men, mood changes were among the most common side effects; irritability/mood alteration is described across the SERM/hypogonadism literature. Frequency appears low (side effects reported in under ~10% of patients) but is real and a reason to stop and seek review.
No known clinically significant renal effects; no adequate human renal-outcome data specific to clomiphene in men.
No consistent erythrocytosis/polycythemia signal has been reported (a contrast with exogenous testosterone), but hematologic parameters are not systematically reported across trials, so data are limited.
No prominent dermatologic toxicity reported; acne or oily skin is biologically plausible from the rise in testosterone/DHT but is not well quantified in the male clomiphene trials. Limited data.
HPTA suppression & recovery
Suppression: Not suppressive — clomiphene stimulates the HPTA (opposite of anabolic steroids); it raises LH, FSH and endogenous testosterone rather than shutting the axis down
Because clomiphene works by driving the patient's own axis, stopping it removes the pharmacologic stimulation and gonadotropin/testosterone levels return toward the individual's untreated baseline, which may still be low if an underlying hypogonadism exists. It is used by some men as part of post-cycle recovery after anabolic steroid-induced suppression, but the quality of evidence for that specific indication is weak and it does not repair primary testicular damage. Any recovery or post-steroid protocol should be individualized, monitored with serial bloodwork (LH, FSH, total/free testosterone, estradiol), and directed by an endocrinologist or andrologist rather than self-managed. This monograph covers single-SERM use only.
Monitoring
Cadence: Baseline before starting; recheck hormones (testosterone, LH, FSH, estradiol) at roughly 6-12 weeks to confirm response and titrate under clinician guidance, then periodically (e.g. every 6-12 months) during ongoing use; more often if symptoms change. Ophthalmologic assessment if any visual symptoms occur.
- New or worsening visual symptoms — blurred vision, floaters, flashes, shimmering lights, scotomata (stop and get urgent eye evaluation)
- Signs of blood clot: leg swelling/pain, chest pain, shortness of breath, sudden severe headache, unilateral weakness or vision loss (seek emergency care)
- Significant mood change, depression, irritability or anxiety
- Breast tenderness or breast tissue enlargement (rising estradiol)
- Signs of liver problems: jaundice, dark urine, right-upper-quadrant pain
- Persistent headaches
Contraindications
- Known hypersensitivity to clomiphene/clomifene
- Personal history of, or active, venous thromboembolism or thrombophilia (SERM class thrombotic caution)
- Significant hepatic dysfunction or active liver disease
- Pre-existing visual disturbance or retinal/optic pathology (clomiphene can cause visual symptoms that may worsen or mask disease)
- Primary (hypergonadotropic) hypogonadism / testicular failure, where it is ineffective because the testes cannot respond
- Uninvestigated cause of low testosterone (pituitary tumor/hyperprolactinemia, etc.) — needs endocrine work-up before use
- Men actively trying to use it as unsupervised self-medication without baseline labs and clinician oversight
Interaction profile
- MajorWith another SERM: Blood / clotting
- ModerateWith an aromatase inhibitor: Hormonal
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Get a proper diagnostic work-up first: low testosterone should be confirmed on repeat morning labs and its cause investigated (pituitary/prolactin, primary vs secondary) before any SERM is used — clomiphene does not work in primary testicular failure.
- Use only under a clinician (endocrinologist/urologist) with baseline and follow-up bloodwork; do not self-titrate to chase a number. Reported clinical doses in the male literature cluster around 12.5-50 mg daily or every other day, always paired with monitoring and the risks described here.
- Stop and seek urgent eye assessment for any new visual symptoms (blurring, flashes, shimmering, floaters, scotomata) — these are a recognized SERM effect and are a signal to discontinue.
- Seek emergency care for symptoms of a blood clot (leg swelling/pain, chest pain, breathlessness, sudden severe headache, one-sided weakness or vision loss); the SERM class carries a thrombotic caution and clomiphene raises estradiol.
- Monitor and act on rising estradiol effects (breast tenderness/gynecomastia) and on mood changes, depression or irritability — these warrant clinician review and possible discontinuation.
- Do not treat clomiphene as a proven 'post-cycle' or recovery drug after anabolic steroids; evidence for that specific use is weak, it will not reverse primary testicular damage, and recovery should be individualized and physician-supervised.
- Because the zuclomiphene isomer persists for weeks, effects and lab changes can lag dose changes; interpret monitoring with that washout in mind.
- Avoid entirely if you have a personal history of venous thromboembolism, significant liver disease, or a hormone-sensitive contraindication without specialist clearance.
Citations (13)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Clomiphene citrate raises total testosterone in hypogonadal men, with increases also in free testosterone, LH, FSH, SHBG and estradiol; side effects were reported in under ~10% of patients and no serious adverse events were reported across 19 studies (4 RCTs) in 1642 men.
Meta-analysisPMID 34933414 ↗
- 02
In a meta-analysis of randomized controlled trials, SERM therapy (clomiphene/enclomiphene) significantly improved total testosterone, LH and FSH versus placebo, with no significant difference in total testosterone versus testosterone gel.
Meta-analysisClomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.PMID 41066380 ↗
- 03
Clomiphene and enclomiphene citrate significantly increase testosterone in men with obesity-related functional androgen deficiency and may be an effective and safe alternative to testosterone replacement, though long-term safety needs further study.
Meta-analysisSelective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis.PMID 36604313 ↗
- 04
Evidence is insufficient to support routine use of clomiphene, tamoxifen or aromatase inhibitors to optimize semen parameters in men with infertility; trial quality was low and effects versus placebo were not established.
Meta-analysisPharmacological non-hormonal treatment options for male infertility: a systematic review and network meta-analysis.PMID 39075435 ↗
- 05
Exogenous testosterone suppresses spermatogenesis, whereas SERMs such as clomiphene can raise testosterone while preserving fertility in hypogonadal men who wish to retain fertility.
ReviewPMID 29713545 ↗
- 06
Enclomiphene citrate increased serum testosterone, LH and FSH similar to topical testosterone gel while conserving sperm counts in men with secondary hypogonadism in a randomized phase II trial.
RCTEnclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone.PMID 25044085 ↗
- 07
In a randomized double-blind trial, clomiphene 25 mg/day raised testosterone more than anastrozole and increased estradiol (whereas anastrozole lowered it), with no significant change in semen parameters over 12 weeks.
- 08
In an RCT in obese dysmetabolic men on metformin, clomiphene 25 mg/day significantly increased testosterone, LH and FSH and reduced fasting glucose, insulin and HOMA-IR versus placebo.
- 09
Long-term clomiphene therapy (>12 months) in hypogonadal men raised testosterone durably and was associated with improved femoral neck and lumbar spine bone mineral density, with no adverse events reported in a 46-patient cohort.
CohortClomiphene citrate is safe and effective for long-term management of hypogonadism.PMID 22458540 ↗
- 10
In a retrospective cohort of 400 men treated up to 84 months, 8% of those on clomiphene for more than 3 years reported side effects, most commonly mood changes, blurred vision and breast tenderness; no serious adverse event occurred.
CohortLong-Term Safety and Efficacy of Clomiphene Citrate for the Treatment of Hypogonadism.PMID 31216250 ↗
- 11
Clomiphene alters the male steroid profile beyond testosterone, increasing dihydrotestosterone, estradiol and estrone, consistent with stimulation of testicular steroidogenesis.
- 12
Clomiphene is a racemate whose enclomiphene isomer is comparatively short-lived while the zuclomiphene isomer has a very long, flat terminal half-life and long tissue residence, so a single half-life cannot be reliably assigned and washout is prolonged.
CohortSingle-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease.PMID 19033451 ↗
- 13
In a randomized crossover RCT, clomiphene had a neutral-to-slightly-negative effect on overall sexual function versus placebo (higher sexual-desire domain but lower qADAM score), indicating symptomatic benefit is inconsistent.
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice